Family Medicine Doctors in Harrisville, MI Accepting Medicare
6 Family Medicine doctors found. Showing 1 - 6
 Dr. Ashley Kaatz, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 177 N Barlow Rd, Harrisville, MI 48740 Phone: 989-736-8157 Fax: 989-358-3762 |
 Paul R. Troost, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 177 N Barlow Rd, Harrisville, MI 48740 Phone: 989-736-8157 Fax: 989-358-3762 |
Dr. James P. Richards, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 205 N State St, Suite A, Harrisville, MI 48740 Phone: 989-724-5655 Fax: 989-358-3730 |
Dr. Thomas Joseph Marshall, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 177 N Barlow Rd, Harrisville, MI 48740 Phone: 989-736-8157 Fax: 989-358-3762 |
Dr. Kathleen June Dunckel, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 177 N Barlow Rd, Harrisville, MI 48740 Phone: 989-736-3020 Fax: 989-736-8278 |
Dr. John C. Macmaster, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 177 N Barlow Rd, Harrisville, MI 48740 Phone: 989-736-8157 Fax: 989-358-3762 |
News Archive
Scientists develop new synthetic material to grow stem cells
Human pluripotent stem cells, which can become any other kind of body cell, hold great potential to treat a wide range of ailments, including Parkinson's disease, multiple sclerosis and spinal cord injuries. However, scientists who work with such cells have had trouble growing large enough quantities to perform experiments - in particular, to be used in human studies. Furthermore, most materials now used to grow human stem cells include cells or proteins that come from mice embryos, which help stimulate stem-cell growth but would likely cause an immune reaction if injected into a human patient.
Anulex Technologies completes $20M Series E financing round
Anulex Technologies, Inc., a privately held medical device manufacturer focusing on soft tissue Preservation & Anular Repair products, announced the first closing of its fifth round of private equity financing which will total a minimum of $20 million. The Series E round was led by a new unnamed strategic investor with participation from existing investors Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.
CKD-EPI equation may provide more accurate risk prediction of death, ESRD
Kamyar Kalantar-Zadeh, M.D., M.P.H., Ph.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), is the author of an invited editorial in JAMA. The editorial accompanied a study that included data from more than 1 million adults, and indicated the use of a newer risk prediction equation that classified fewer individuals as having chronic kidney disease and more accurately categorized the risk for death and end-stage renal disease.
Eli Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain
Eli Lilly and Company has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the management of chronic pain.
› Verified 5 days ago
Family Medicine
Emergency Medicine
Psychiatry & Neurology
General Practice